Elevated Healthcare Expenditure in Emerging Economies to Boost Market in Coming Years
Healthcare budget allocations help countries strengthen workforces and improve this sector's productivity, thereby contributing to economic performance. Rapid economic developments allow developing countries to raise their healthcare expenditures, enabling them to establish better medical service infrastructure by leveraging technological advancements. The Government of India, through its National Health Authority agency, implemented Ayushman Bharat – Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) in 2019. This scheme has facilitated free/affordable treatment for cancer patients in the country. As per the data published by the National Health Authority of India, ~470,133 cancer cases were treated under AB-PMJAY in 2019. Such initiatives are likely to provide lucrative opportunities for companies in the blood transfusion diagnostics market to introduce advanced technologies for the blood transfusion diagnostics market in Asia Pacific.
Market Overview
China dominated the blood transfusion diagnostics market in Asia Pacific in 2022. The market growth in China is attributed to the increased use of advanced technologies in blood-related diagnoses, followed by a surge in the number of blood donation camps and blood banks in the country. The nation has a blood donation law in place that allows voluntary unpaid blood donation, and the donated blood can only be used for clinical practice. China's National Health Commission recorded 15.53 million blood donations in 2020, despite the pandemic-related restrictions. This figure is 40-times more than that recorded in 1998. According to Xinhua news, from January to April 2021, 5.12 million blood donations were registered nationwide. Therefore, the increasing number of blood donations for clinical use leads to high demand for blood transfusion diagnostics to screen the blood groups.
Strategic insights for the Asia-Pacific Blood Transfusion Diagnostics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market. The geographic scope of the Asia-Pacific Blood Transfusion Diagnostics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.Asia-Pacific Blood Transfusion Diagnostics Strategic Insights
Asia-Pacific Blood Transfusion Diagnostics Report Scope
Report Attribute
Details
Market size in 2022
US$ 875.20 Million
Market Size by 2028
US$ 1,380.34 Million
Global CAGR (2022 - 2028)
7.9%
Historical Data
2020-2021
Forecast period
2023-2028
Segments Covered
By Product
By Application
By End User
Regions and Countries Covered
Asia-Pacific
Market leaders and key company profiles
Asia-Pacific Blood Transfusion Diagnostics Regional Insights
APAC Blood Transfusion Diagnostics Market Segmentation
The APAC blood transfusion diagnostics market is segmented based on product, application, end user, and country.
Abbott; BAG Diagnostics GmbH; Bio-Rad Laboratories, Inc.; DiaSorin S.p.A.; F. Hoffmann-La Roche Ltd; Grifols, S.A.; Immucor, Inc.; Ortho Clinical Diagnostics (QuidelOrtho Corporation); Quotient Limited; and Thermo Fisher Scientific Inc. are the leading companies operating in the APAC blood transfusion diagnostics market.
The Asia-Pacific Blood Transfusion Diagnostics Market is valued at US$ 875.20 Million in 2022, it is projected to reach US$ 1,380.34 Million by 2028.
As per our report Asia-Pacific Blood Transfusion Diagnostics Market, the market size is valued at US$ 875.20 Million in 2022, projecting it to reach US$ 1,380.34 Million by 2028. This translates to a CAGR of approximately 7.9% during the forecast period.
The Asia-Pacific Blood Transfusion Diagnostics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia-Pacific Blood Transfusion Diagnostics Market report:
The Asia-Pacific Blood Transfusion Diagnostics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia-Pacific Blood Transfusion Diagnostics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia-Pacific Blood Transfusion Diagnostics Market value chain can benefit from the information contained in a comprehensive market report.